{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:34Z","timestamp":1792784974065,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Imperial Tobacco Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nicotine replacement therapies (NRTs) are intended for short-term use to help cigarette smokers to quit. Some smokers find NRTs ineffective or seek a more satisfactory source of nicotine. Tobacco-free oral nicotine pouch (NP) products have emerged as a potential reduced risk product compared with cigarettes and other tobacco products. In a randomised crossover clinical study, thirty-four healthy adult smokers were enrolled and their nicotine C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0-T<\/jats:sub>\n                    determined for three 4\u00a0mg nicotine products (NP, gum, lozenge) under fasting conditions. The NP, lozenge and gum mean C\n                    <jats:sub>max<\/jats:sub>\n                    values were 8.5, 8.3 and 4.4\u00a0ng\/mL, AUC\n                    <jats:sub>0-T<\/jats:sub>\n                    values were 30.6, 31.5 and 14.3\u00a0ng*h\/mL, respectively. The NP showed similar nicotine bioavailability to the lozenge (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.6526 (C\n                    <jats:sub>max<\/jats:sub>\n                    ),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20091.0000 (AUC\n                    <jats:sub>0-T<\/jats:sub>\n                    )), and superior bioavailability to the gum (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2009&lt;\u20090.0001 for C\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0-T<\/jats:sub>\n                    ). Compared with the lozenge, the NP demonstrated greater product satisfaction with a higher number of positive responses to subjective satisfaction questions. All products were judged to be well-tolerated; the incidence of minor adverse events was lower for the NP (18.2%) than the lozenge (33.3%) or gum (18.8%). In summary, NPs may provide smokers with a more satisfying alternative nicotine source as compared to the reference NRTs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Study Registry\/Registered Trial No:<\/jats:italic>\n                    ISRCTN\/ISRCTN65708311.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-10544-x","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T07:04:29Z","timestamp":1651129469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products"],"prefix":"10.1038","volume":"12","author":[{"given":"David","family":"Azzopardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ebajemito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar M.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Thissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hardie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Voisine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Mullard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"10544_CR1","unstructured":"US Department of Health and Human Services. The health consequences of smoking\u201350 years of progress: A report of the Surgeon General. Atlanta: Centers for Disease Control and Prevention. Available from: https:\/\/www.hhs.gov\/surgeongeneral\/reports-and-publications\/tobacco\/index.html [Accessed 01 February 2021] (2014)."},{"key":"10544_CR2","volume-title":"The chemical components of tobacco and tobacco smoke","author":"A Rodgman","year":"2013","unstructured":"Rodgman, A. & Perfetti, T. A. The chemical components of tobacco and tobacco smoke 2nd edn. (CRC Press, 2013).","edition":"2"},{"issue":"4","key":"10544_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/tc.12.4.424","volume":"12","author":"J Fowles","year":"2003","unstructured":"Fowles, J. & Dybing, E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob. Control. 12(4), 424\u2013430. https:\/\/doi.org\/10.1136\/tc.12.4.424 (2003).","journal-title":"Tob. Control."},{"key":"10544_CR4","unstructured":"Gottlieb, S. Protecting American families: Comprehensive approach to nicotine and tobacco. Speech by Scott Gottlieb, FDA, White Oak, MD. Available from: https:\/\/www.fda.gov\/news-events\/speeches-fda-officials\/protecting-american-families-comprehensive-approach-nicotine-and-tobacco-06282017 [Accessed 01 February 2021] (2017)."},{"key":"10544_CR5","unstructured":"Royal College of Physicians. Nicotine with smoke: Tobacco harm reduction. London: RCP. Available from: https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/nicotine-without-smoke-tobacco-harm-reduction [Accessed 01 February 2021] (2016)."},{"issue":"24","key":"10544_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra0809890","volume":"362","author":"NL Benowitz","year":"2010","unstructured":"Benowitz, N. L. Nicotine addiction. N. Engl. J. Med. 362(24), 2295\u20132303. https:\/\/doi.org\/10.1056\/NEJMra0809890 (2010).","journal-title":"N. Engl. J. Med."},{"key":"10544_CR7","unstructured":"Public Health England. Health matters: stopping smoking - what works? London: Public Health England. Available from: https:\/\/www.gov.uk\/government\/publications\/health-matters-stopping-smoking-what-works\/health-matters-stopping-smoking-what-works [Accessed 01 February 2021] (2019)."},{"key":"10544_CR8","unstructured":"Royal College of Physicians. Harm reduction in nicotine addiction: helping people who can\u2019t quit. A report by the tobacco advisory group of the Royal College of Physicians. London: RCP (2007)."},{"key":"10544_CR9","unstructured":"Eriksen, M., Mackay, J. & Ross, H. The Tobacco Atlas. Fourth Edition. American Cancer Society and World Lung Foundation (2012)."},{"issue":"6","key":"10544_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011045","volume":"6","author":"M Chaiton","year":"2016","unstructured":"Chaiton, M. et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open 6(6), e011045. https:\/\/doi.org\/10.1136\/bmjopen-2016-011045 (2016).","journal-title":"BMJ Open"},{"issue":"4","key":"10544_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1176\/ajp.134.4.439","volume":"134","author":"NG Schneider","year":"1977","unstructured":"Schneider, N. G., Popek, P., Jarvik, M. E. & Gritz, E. R. The use of nicotine gum during cessation of smoking. Am. J. Psychiatry 134(4), 439\u2013440. https:\/\/doi.org\/10.1176\/ajp.134.4.439 (1977).","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10544_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1360-0443.1991.tb01825.x","volume":"86","author":"MA Russell","year":"1991","unstructured":"Russell, M. A. The future of nicotine replacement. Br. J. Addict. 86(5), 653\u2013658. https:\/\/doi.org\/10.1111\/j.1360-0443.1991.tb01825.x (1991).","journal-title":"Br. J. Addict."},{"issue":"5","key":"10544_CR13","doi-asserted-by":"publisher","first-page":"CD000146","DOI":"10.1002\/14651858.CD000146.pub5","volume":"5","author":"J Hartmann-Boyce","year":"2018","unstructured":"Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C. & Lancaster, T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst. Rev. 5(5), CD000146. https:\/\/doi.org\/10.1002\/14651858.CD000146.pub5 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10544_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200140090-00003","volume":"40","author":"NG Schneider","year":"2001","unstructured":"Schneider, N. G., Olmstead, R. E., Franzon, M. A. & Lunell, E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin. Pharmacokinet. 40(9), 661\u2013684. https:\/\/doi.org\/10.2165\/00003088-200140090-00003 (2001).","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10544_CR15","first-page":"811","volume":"7","author":"J Le Houezec","year":"2003","unstructured":"Le Houezec, J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int. J. Tuberc. Lung. Dis. 7(9), 811\u2013819 (2003).","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"10544_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","volume":"192","author":"NL Benowitz","year":"2009","unstructured":"Benowitz, N. L., Hukkanen, J. & Jacob, P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol. 192, 29\u201360. https:\/\/doi.org\/10.1007\/978-3-540-69248-5_2 (2009).","journal-title":"Handb. Exp. Pharmacol."},{"key":"10544_CR17","doi-asserted-by":"publisher","DOI":"10.17226\/10029","volume-title":"Clearing the smoke: assessing the science base for tobacco harm reduction","year":"2001","unstructured":"Stratton, K. et al. (eds) Clearing the smoke: assessing the science base for tobacco harm reduction (National Academy Press, US, Washington, DC, 2001). https:\/\/doi.org\/10.17226\/10029."},{"key":"10544_CR18","unstructured":"Royal College of General Practitioners. RCGP Position Statement on the use of electronic nicotine vapour products (e-cigarettes). September 2017: https:\/\/www.rcgp.org.uk\/-\/media\/Files\/Policy\/2017\/RCGP-E-cig-position-statement-sept-2017.ashx?la=en [Accessed 01 February 2021] (2017)."},{"key":"10544_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.yrtph.2017.09.008","volume":"90","author":"J Murphy","year":"2017","unstructured":"Murphy, J. et al. Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette. Regul. Toxicol. Pharmacol. 90, 342\u2013357. https:\/\/doi.org\/10.1016\/j.yrtph.2017.09.008 (2017).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10544_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02798-6","author":"N Gale","year":"2021","unstructured":"Gale, N. et al. Changes in biomarkers after 180 days of tobacco heating product use: a randomised trial. Intern. Emerg. Med. https:\/\/doi.org\/10.1007\/s11739-021-02798-6 (2021).","journal-title":"Intern. Emerg. Med."},{"key":"10544_CR21","unstructured":"US Food and Drug Administration. Guidance for industry: Modified Risk Tobacco Product applications. Silver Spring, MA: FDA, Available from https:\/\/www.fda.gov\/media\/83300\/download [Accessed 01 February 2021] (2012)."},{"key":"10544_CR22","unstructured":"US Food and Drug Administration. FDA grants first-ever modified risk orders to eight smokeless tobacco products. Silver Spring, MD: FDA. Available from https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-first-ever-modified-risk-orders-eight-smokeless-tobacco-products [Accessed 01 February 2021] (2019)."},{"issue":"4","key":"10544_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/tc.12.4.349","volume":"12","author":"J Foulds","year":"2003","unstructured":"Foulds, J., Ramstrom, L., Burke, M. & Fagerstr\u00f6m, K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob. Control. 12(4), 349\u2013359. https:\/\/doi.org\/10.1136\/tc.12.4.349 (2003).","journal-title":"Tob. Control."},{"key":"10544_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60677-1","author":"CE Gartner","year":"2007","unstructured":"Gartner, C. E. et al. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(07)60677-1 (2007).","journal-title":"Lancet"},{"key":"10544_CR25","unstructured":"ENVIRON. Review of the scientific literature on snus. Arlington, VA: ENVIRON. Available from: https:\/\/www.swedishmatch.com\/globalassets\/documents\/other\/environ-review-of-the-scientific-literature-on-snus-3-31-10.pdf [Accessed 01 February 2021] (2010)."},{"issue":"2","key":"10544_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.yrtph.2010.12.002","volume":"59","author":"PN Lee","year":"2011","unstructured":"Lee, P. N. Summary of the epidemiological evidence relating snus to health. Regul. Toxicol. Pharmacol. 59(2), 197\u2013214. https:\/\/doi.org\/10.1016\/j.yrtph.2010.12.002 (2011).","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10544_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yrtph.2013.02.010","volume":"66","author":"PN Lee","year":"2013","unstructured":"Lee, P. N. The effect on health of switching from cigarettes to snus\u2014a review. Regul. Toxicol. Pharmacol. 66(1), 1\u20135. https:\/\/doi.org\/10.1016\/j.yrtph.2013.02.010 (2013).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10544_CR28","unstructured":"Ramboll. Systematic review and update of the literature on the health effects of Swedish snus. Arlington, VA: Ramboll. Available from: https:\/\/www.swedishmatch.com\/globalassets\/documents\/other\/ramboll-health-effects-update-report_20190513.pdf [Accessed 01 February 2021] (2019)."},{"key":"10544_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12954-019-0335-1","volume":"16","author":"E Clarke","year":"2019","unstructured":"Clarke, E. et al. Snus: a compelling harm reduction alternative to cigarettes. Harm Reduct. J. 16, 62. https:\/\/doi.org\/10.1186\/s12954-019-0335-1 (2019).","journal-title":"Harm Reduct. J."},{"issue":"6","key":"10544_CR30","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374\u20131403. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.027 (2013).","journal-title":"Eur. J. Cancer"},{"key":"10544_CR31","unstructured":"Swedish Match. The Swedish Experience. Stockholm, Sweden: Swedish Match. Available from: https:\/\/www.swedishmatch.com\/Snus-and-health\/The-Swedish-experience\/ [Accessed 01 February 2021] (2019)."},{"key":"10544_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/01480545.2021.1925691","author":"D Azzopardi","year":"2021","unstructured":"Azzopardi, D., Liu, C. & Murphy, J. Chemical characterization of tobacco-free \u201cmodern\u201d oral nicotine pouches and their position on the toxicant and risk continuums. Drug Chem. Toxicol. https:\/\/doi.org\/10.1080\/01480545.2021.1925691 (2021).","journal-title":"Drug Chem. Toxicol."},{"key":"10544_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111713","volume":"145","author":"E Bishop","year":"2020","unstructured":"Bishop, E. et al. An approach for the extract generation and toxicological assessment of tobacco-free \u201cmodern\u201d oral nicotine pouches. Food Chem. Toxicol. 145, 111713. https:\/\/doi.org\/10.1016\/j.fct.2020.111713 (2020).","journal-title":"Food Chem. Toxicol."},{"key":"10544_CR34","unstructured":"TPD. Comparative Bioavailability Standards: Formulations used for Systemic Effects. Available from https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/conduct-analysis-comparative.html [Accessed 01 February 2021] (2018)."},{"issue":"5","key":"10544_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/1462220031000158690","volume":"5","author":"JH Choi","year":"2003","unstructured":"Choi, J. H., Dresler, C. M., Norton, M. R. & Strahs, K. R. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob. Res. 5(5), 635\u2013644. https:\/\/doi.org\/10.1080\/1462220031000158690 (2003).","journal-title":"Nicotine Tob. Res."},{"issue":"12","key":"10544_CR36","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/ntr\/ntr139","volume":"13","author":"H Kraiczi","year":"2011","unstructured":"Kraiczi, H., Hansson, A. & Perfekt, R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine Tob. Res. 13(12), 1176\u20131182. https:\/\/doi.org\/10.1093\/ntr\/ntr139 (2011).","journal-title":"Nicotine Tob. Res."},{"issue":"7","key":"10544_CR37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/ntr\/ntr044","volume":"13","author":"E Lunell","year":"2011","unstructured":"Lunell, E. & Curvall, M. Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. Nicotine Tob. Res. 13(7), 573\u2013578. https:\/\/doi.org\/10.1093\/ntr\/ntr044 (2011).","journal-title":"Nicotine Tob. Res."},{"issue":"1","key":"10544_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/ntr\/nts123","volume":"15","author":"H Digard","year":"2013","unstructured":"Digard, H., Proctor, C., Kulasekaran, A., Malmqvist, U. & Richter, A. Determination of nicotine absorption from multiple tobacco products and nicotine gum. Nicotine Tob. Res. 15(1), 255\u2013261. https:\/\/doi.org\/10.1093\/ntr\/nts123 (2013).","journal-title":"Nicotine Tob. Res."},{"issue":"4","key":"10544_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ntr\/ntw211","volume":"19","author":"A Hansson","year":"2017","unstructured":"Hansson, A., Rasmussen, T. & Kraiczi, H. Single-dose and multiple-dose pharmacokinetics of nicotine 6 mg gum. Nicotine Tob. Res. 19(4), 477\u2013483. https:\/\/doi.org\/10.1093\/ntr\/ntw211 (2017).","journal-title":"Nicotine Tob. Res."},{"issue":"17","key":"10544_CR40","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s00213-017-4665-y","volume":"234","author":"MF Stiles","year":"2017","unstructured":"Stiles, M. F. et al. Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability. Psychopharmacology 234(17), 2643\u20132655. https:\/\/doi.org\/10.1007\/s00213-017-4665-y (2017).","journal-title":"Psychopharmacology"},{"key":"10544_CR41","doi-asserted-by":"publisher","first-page":"108395","DOI":"10.1016\/j.drugalcdep.2020.108395","volume":"217","author":"NI Goldenson","year":"2020","unstructured":"Goldenson, N. I., Buchhalter, A. R., Augustson, E. M., Rubinstein, M. L. & Henningfield, J. E. Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult smokers. Drug Alcohol Depend. 217, 108395. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108395 (2020).","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10544_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/cpdd.909","volume":"10","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Characterization of the abuse potential in adult smokers of a novel oral tobacco product relative to combustible cigarettes and nicotine polacrilex gum. Clin. Pharmacol. Drug Dev. 10(3), 241\u2013250. https:\/\/doi.org\/10.1002\/cpdd.909 (2021).","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"5","key":"10544_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/ntr\/ntv220","volume":"18","author":"P Picavet","year":"2016","unstructured":"Picavet, P., Haziza, C., Lama, N., Weitkunat, R. & L\u00fcdicke, F. Comparison of the Pharmacokinetics of Nicotine Following Single and Ad Libitum Use of a Tobacco Heating System or Combustible Cigarettes. Nicotine Tob. Res. 18(5), 557\u2013563. https:\/\/doi.org\/10.1093\/ntr\/ntv220 (2016).","journal-title":"Nicotine Tob. Res."},{"issue":"7","key":"10544_CR44","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00213-018-4904-x","volume":"235","author":"MF Stiles","year":"2018","unstructured":"Stiles, M. F. et al. Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum. Psychopharmacology 235(7), 2077\u20132086. https:\/\/doi.org\/10.1007\/s00213-018-4904-x (2018).","journal-title":"Psychopharmacology"},{"issue":"4","key":"10544_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/add.14884","volume":"115","author":"G St Helen","year":"2020","unstructured":"St Helen, G. et al. Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users. Addiction 115(4), 757\u2013767. https:\/\/doi.org\/10.1111\/add.14884 (2020).","journal-title":"Addiction"},{"issue":"2","key":"10544_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13318-021-00742-9","volume":"47","author":"M McEwan","year":"2022","unstructured":"McEwan, M. et al. A randomised study to investigate the nicotine pharmacokinetics of oral nicotine pouches and a combustible cigarette. Eur. J. Drug Metab. Pharmacokinet. 47(2), 211\u2013221. https:\/\/doi.org\/10.1007\/s13318-021-00742-9 (2022).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"10","key":"10544_CR47","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/ntr\/ntaa068","volume":"22","author":"E Lunell","year":"2020","unstructured":"Lunell, E., Fagerstr\u00f6m, K., Hughes, J. & Pendrill, R. Pharmacokinetic comparison of a novel non-tobacco-based nicotine pouch (ZYN\u00ae) with conventional, tobacco-based Swedish snus and American moist snuff. Nicotine Tob. Res. 22(10), 1757\u20131763. https:\/\/doi.org\/10.1093\/ntr\/ntaa068 (2020).","journal-title":"Nicotine Tob. Res."},{"key":"10544_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05948-y","author":"J Rensch","year":"2021","unstructured":"Rensch, J. et al. Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!\u00ae nicotine pouches compared to combustible cigarettes. Psychopharmacology https:\/\/doi.org\/10.1007\/s00213-021-05948-y (2021).","journal-title":"Psychopharmacology"},{"issue":"4","key":"10544_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/ajad.13020","volume":"29","author":"N Plurphanswat","year":"2020","unstructured":"Plurphanswat, N., Hughes, J. R., Fagerstr\u00f6m, K. & Rodu, B. Initial information on a novel nicotine product. Am. J. Addict. 29(4), 279\u2013286. https:\/\/doi.org\/10.1111\/ajad.13020 (2020).","journal-title":"Am. J. Addict."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10544-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:09:52Z","timestamp":1669324192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10544-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10544"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10544-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Imperial Tobacco Canada (ITC) funded this study. ITC is a subsidiary of BAT, a company that manufactures tobacco and nicotine products. All authors are or were employees of BAT, ITC or R.J. Reynolds Tobacco Company, a wholly-owned subsidiary of BAT.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6949"}}